Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U04 Substudy 04C: MK-2870 + enfortumab vedotin with or without pembrolizumab in advanced urothelial carcinoma
2023-506387-14-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial in transitional cell carcinoma (TCC) comparing MK-2870 + enfortumab vedotin with MK-2870 + enfortumab vedotin + Keytruda (2 arms). Primary endpoints: Percentage of participants with dose-limiting toxicities, Percentage of participants who experienced at least one adverse event and 2 more. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-506387-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506387-14-00.